Aeronide

Aeronide

budesonide

Manufacturer:

Inpac Pharma

Distributor:

Endure Medical

Marketer:

Endure Medical
Concise Prescribing Info
Contents
Budesonide
Indications/Uses
Maintenance treatment of bronchial asthma as prophylactic therapy.
Dosage/Direction for Use
Asthma Adult & childn >12 yr 200-1,600 mcg daily divided into 2-4 administrations. Mild asthmatics Up to 400 mcg once daily for symptom control, maintenance dose should be individualised & lowest dose. Recommended dose: 100-400 mcg daily. May be given once daily or bid. Less severe cases Patient w/ mild to moderate asthma who have not previously received inhaled glucocorticosteroids 200-400 mcg bid, w/ mild to moderate asthma already controlled on inhaled steroids Up to 800 mcg bid. Severe cases 800-1,600 mcg daily bid. Severe asthma & during exacerbations Divide daily dose into 3-4 administrations daily. Childn ≥7 yr 200-800 mcg daily divided into 2-4 administrations. Childn w/ mild to moderate asthma who have not previously received inhaled glucocorticosteroids, or are already controlled on inhaled steroids 200-400 mcg daily divided into 2 administrations. Severe asthma May be increased up to 800 mcg daily. Childn 1-8 yr w/ previous therapy of bronchodilator alone 500 mcg daily either once daily or bid in divided doses. Max: 500 mcg daily; w/ previous therapy of inhaled corticosteroids 500 mcg daily either once daily or bid in divided doses. Max: 1,000 mcg daily; w/ previous therapy of oral corticosteroid 1,000 mcg daily either as 500 mcg bid or 1,000 mcg once daily. Max: 1,000 mcg daily. Symptomatic childn not responding nonsteroidal therapy Initially 250 mcg daily may be considered.
Contraindications
Hypersensitivity. Primary status asthmaticus or other acute episodes of asthma where intensive measures are required.
Special Precautions
Steroid w/drawal. Resume oral corticosteroids immediately in patients w/drawn from systemic corticosteroids during periods of stress or severe asthma attack. Transfer of patients from systemic corticosteroid therapy to budesonide may unmask allergic conditions previously suppressed by systemic corticosteroid therapy. Suppression of immune system. Not indicated for rapid relief of bronchospasm or other acute episodes of asthma. Bronchospasm w/ immediate increase in wheezing. Systemic corticosteroid effects eg, hypercorticism & adrenal suppression. Glaucoma, increased IOP & cataracts. Patients w/ active or quiescent TB infection of resp tract, untreated systemic fungal, bacterial, viral or parasitic infections, or ocular herpes simplex. Reduction of growth velocity in childn or teenagers. Adrenal suppression in prolonged treatment w/ high doses. Avoid concomitant use w/ ketoconazole & itraconazole or other potent CYP3A4 inhibitors. Hepatic impairment. Pregnancy & lactation.
Drug Interactions
Increased mean plasma conc w/ ketoconazole. Inhibition of metabolism & increased exposure w/ itraconazole, clarithromycin, & erythromycin. Decreased clearance & increased oral bioavailability w/ cimetidine.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
Presentation/Packing
Form
Aeronide MDI 200 mcg/actuation
Packing/Price
200 actuation x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in